CYXO.ST Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 18:05):

Cyxone AB (publ), a clinical biotech company, develops disease modifying therapies for rheumatoid arthritis, multiple sclerosis, and treatments for virally induced acute respiratory disorders...

Stats
Dzisiejszy wolumen	1.15M
Średni wolumen	739 347
Kapitalizacja rynkowa	9.14M
EPS	SEK0 ( 2024-02-23 )
Następna data zysków	( SEK0 ) 2024-05-10
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-0.220
ATR14	SEK0.00100 (1.08%)

Wolumen Korelacja

Długi: -0.18 (neutral)

Krótki: 0.58 (weak)

Signal:(49.043) Neutral

Cyxone AB (publ) Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cyxone AB (publ) Korelacja - Waluta/Towar

0.00
( neutral )

0.11
( neutral )

Cyxone AB (publ) Finanse

Annual	2023
Przychody:	SEK0
Zysk brutto:	SEK-2.54M (0.00 %)
EPS:	SEK-0.220

FY	2023
Przychody:	SEK0
Zysk brutto:	SEK-2.54M (0.00 %)
EPS:	SEK-0.220

FY	2022
Przychody:	SEK6.40M
Zysk brutto:	SEK4.16M (64.98 %)
EPS:	SEK-0.430

FY	2021
Przychody:	SEK0.00
Zysk brutto:	SEK0.00 (0.00 %)
EPS:	SEK-0.429

Financial Reports:

No articles found.

Cyxone AB (publ)

Cyxone AB (publ), a clinical biotech company, develops disease modifying therapies for rheumatoid arthritis, multiple sclerosis, and treatments for virally induced acute respiratory disorders. Its development portfolio comprises Rabeximod in a clinical Phase II program for rheumatoid arthritis and Covid-19 infections; and T20K, a Phase 1 candidate drug for the treatment of multiple sclerosis. The company was incorporated in 2015 and is based in Malmö, Sweden.